| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF02214872 |
| P698 | PubMed publication ID | 7859585 |
| P2093 | author name string | Lam SK | |
| Berlin RG | |||
| Hawkey CJ | |||
| Langman MJ | |||
| Smallwood RA | |||
| Festen HP | |||
| Parkinson A | |||
| Lundborg P | |||
| Castagnoli N | |||
| P2860 | cites work | Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines | Q24339615 |
| Endocrine adverse effects of omeprazole | Q28316627 | ||
| Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion | Q28318405 | ||
| Cimetidine and bradycardia | Q28318448 | ||
| Cimetidine hepatitis | Q28326883 | ||
| Acute interstitial nephritis due to omeprazole | Q28327283 | ||
| Bone-Marrow Suppression Associated with Cimetidine | Q28327982 | ||
| Cimetidine: Does Neurotoxicity Occur? Report of Three Cases | Q28329647 | ||
| Cimetidine cholestatic jaundice in children | Q28332330 | ||
| First-degree atrioventricular block in a young duodenal ulcer patient treated with a standard oral dose of ranitidine | Q33169152 | ||
| Mechanism of ranitidine associated anemia | Q33433475 | ||
| Clinically important adverse effects and drug interactions with H2-receptor antagonists: an update | Q33444086 | ||
| Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. | Q34037250 | ||
| A study of the interaction between omeprazole and cyclosporine in renal transplant patients | Q34403554 | ||
| Effect of cimetidine on gonadal function in man | Q34449895 | ||
| Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up | Q34487626 | ||
| Ranitidine does not affect gonadal function in man | Q34513180 | ||
| Influence of cimetidine on verapamil kinetics and dynamics | Q70615871 | ||
| Cimetidine in pregnancy: apparent transient liver impairment in the newborn | Q70645299 | ||
| [The effect of cimetidine on the metabolism and effects of alcohol] | Q70798111 | ||
| Effects of cimetidine on pituitary function: Alterations in hormone secretion profiles | Q70999288 | ||
| Inhibitory effect of cimetidine on liver regeneration after two-thirds hepatectomy in rats | Q71020910 | ||
| Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model | Q71131291 | ||
| Prophylaxis of upper gastrointestinal bleeding with cimetidine in patients undergoing partial hepatectomy | Q71382424 | ||
| Central nervous system-mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia | Q71401949 | ||
| Interactions of nitrogen heterocycles with cytochrome P-450 and monooxygenase activity | Q71423394 | ||
| Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone | Q71468820 | ||
| Bridging hepatic necrosis associated with cimetidine | Q71499725 | ||
| Cimetidine and polymyositis | Q71773920 | ||
| Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, nonalcoholic men | Q72212035 | ||
| Inotropic effects of histamine in human myocardium: differentiation between positive and negative components | Q72381812 | ||
| Omeprazole, a gastric 'proton pump inhibitor': lack of effect on renal handling of electrolytes and urinary acidification | Q72389382 | ||
| Effects of cimetidine, ranitidine, and antacid on renal function | Q72392835 | ||
| Effect of the new H2-receptor antagonist ranitidine on plasma prolactin levels in duodenal ulcer patients | Q72505007 | ||
| Ranitidine also reduces liver blood flow | Q72517426 | ||
| The acute and long term effect of the H2-receptor antagonists cimetidine and ranitidine on the pituitary-gonadal axis in men | Q72555196 | ||
| [Chronic toxicity study of ranitidine hydrochloride orally administered in rats] | Q72555785 | ||
| Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial | Q72556156 | ||
| Effects of cimetidine and ranitidine on delayed-type hypersensitivity | Q72557795 | ||
| Side effects of histamine2-receptor antagonists | Q72561677 | ||
| Negative inotropic effect of some H2-receptor antagonists on the isolated human atria | Q72566710 | ||
| Ranitidine and confusion | Q72578218 | ||
| Omeprazole: no evidence for frequent hepatic reactions | Q72580565 | ||
| In Vivo Interactions Between H2-Receptor Antagonists and Ethanol Metabolism in Man and in Rats | Q72592683 | ||
| Drug interactions involving cimetidine--mechanisms, documentation, implications | Q72601853 | ||
| Renal function and cimetidine. Urinary albumin and beta 2-microglobulin excretion and creatine clearance during cimetidine treatment | Q72635027 | ||
| Effects of two histamine H2-receptor blocking drugs on basal levels of gonadotrophins, prolactin, testosterone and oestradiol-17β during treatment of duodenal ulcer in male patients | Q72885182 | ||
| Possible ranitidine hepatitis | Q72918738 | ||
| Comparison between dose-responses of prolactin, thyroid stimulating hormone and growth hormone to two different histamine H-2 receptor antagonists in normal men | Q72920059 | ||
| Oral ranitidine in labour | Q93610782 | ||
| Possible Ranitidine Hepatotoxicity | Q70221450 | ||
| Effects of cimetidine on the elimination and actions of ethanol | Q70232988 | ||
| Cimetidine and renal allograft rejection | Q70251099 | ||
| Cimetidine and thrombocytopenia | Q70263797 | ||
| Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release | Q70290554 | ||
| Evidence for induction of hepatic microsomal cytochrome P-450 by cimetidine: binding and kinetic studies | Q70291786 | ||
| Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism | Q70292706 | ||
| Cimetidine-induced mania | Q70491579 | ||
| Ranitidine has no effect on postbreakfast ethanol absorption | Q70539273 | ||
| Cimetidine induced arrhythmias | Q70543078 | ||
| Cancer occurrence in a cohort of patients treated with cimetidine | Q34532561 | ||
| Active proton secretion and potassium absorption in the rabbit outer medullary collecting duct. Functional evidence for proton-potassium-activated adenosine triphosphatase | Q34577970 | ||
| No detectable concentrations of oxmetidine but measurable concentrations of cimetidine in cerebrospinal fluid (CSF) during multiple dose treatment | Q34621218 | ||
| Dose and concentration dependent effect of ranitidine on procainamide disposition and renal clearance in man | Q34621491 | ||
| High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism | Q34637307 | ||
| Focus on misoprostol: review of worldwide safety data. | Q34685591 | ||
| Cimetidine, a Histamine H2Receptor Antagonist, Occupies Androgen Receptors* | Q34697969 | ||
| Effect of cimetidine on portal hypertension in cirrhotic patients. | Q34750960 | ||
| Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. | Q34764885 | ||
| Influence of cimetidine on pharmacokinetics of propranolol | Q34780424 | ||
| Postmarketing surveillance of the safety of cimetidine: 12 month mortality report | Q34993287 | ||
| Chronic active hepatitis associated with cimetidine | Q35707957 | ||
| Ouabain-insensitive K-adenosine triphosphatase in distal nephron segments of the rabbit | Q35811612 | ||
| Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretation | Q36422602 | ||
| The drug interaction potential of ranitidine: an update | Q36881820 | ||
| Omeprazole drug interaction studies | Q36890310 | ||
| Effects of antacids on the clinical pharmacokinetics of drugs. An update | Q37583868 | ||
| Cimetidine: an immunomodulator | Q37850684 | ||
| Side effects of anti-ulcer prostaglandins: an overview of the worldwide clinical experience. | Q38237842 | ||
| Effect of cimetidine and ranitidine on cardiovascular drugs | Q38655898 | ||
| Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases | Q38672468 | ||
| Safety profile of omeprazole. Adverse events with short-term treatment | Q38749255 | ||
| Omeprazole: pharmacology, pharmacokinetics and interactions | Q38749269 | ||
| Cimetidine, an H2-antihistamine, stimulates prolactin secretion in man | Q39155812 | ||
| Characterization and development of cimetidine as a histamine H2-receptor antagonist | Q39179168 | ||
| The use of gastrointestinal drugs during pregnancy and lactation | Q39397204 | ||
| Adverse reactions and interactions with H2-receptor antagonists | Q39460908 | ||
| Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo | Q39463874 | ||
| Hepatic effects of drugs used in the treatment of peptic ulcer disease | Q39464423 | ||
| A pharmacokinetic profile of nizatidine in man. | Q39465653 | ||
| Hepatotoxic and hepatoprotective potential of histamine (H2)-receptor antagonists | Q39465764 | ||
| Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential | Q39471071 | ||
| Haematological adverse effects of histamine H2-receptor antagonists | Q39471834 | ||
| Ranitidine versus cimetidine. A comparison of their potential to cause clinically important drug interactions | Q39513613 | ||
| Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. | Q44306866 | ||
| Stimulation of prolactin release by intravenous cimetidine: a dose-response study | Q44485860 | ||
| The effects of omeprazole on endocrine function in man. | Q44538249 | ||
| Haemodynamic effects of famotidine and cimetidine in critically ill patients | Q44625105 | ||
| Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes | Q45082457 | ||
| Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents | Q45142520 | ||
| Influence of histamine receptors on basal left ventricular contractile tone in humans: assessment using the H2 receptor antagonist famotidine and the beta-adrenoceptor antagonist esmolol as pharmacologic probes | Q45347707 | ||
| Cholestatic hepatosis under Cimetidine | Q46791421 | ||
| An evaluation of the anti-androgen effects associated with H2 antagonist therapy | Q48256546 | ||
| Cimetidine-induced prolactin release: possible involvement of the GABA-ergic system | Q48517645 | ||
| Effects of histamine, H1- and H2-receptor antagonists on the activity of serotonergic neurons in the dorsal raphe nucleus. | Q48722769 | ||
| The Effect of Histamine Stimulation and H2-Receptor Inhibition on the Pituitary Prolactin and ACTH Release and on Cortisol Secretion in Human Males | Q48857759 | ||
| Prenatal and neonatal exposure to cimetidine results in gonadal and sexual dysfunction in adult males | Q49075478 | ||
| Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. | Q51607387 | ||
| [4 weeks' administration of omeprazole: effect on acid behavior and basal hormone levels] | Q51642539 | ||
| Effect of single dose of omeprazole on the gastrointestinal peptide response to food | Q51643615 | ||
| Reduction of liver blood flow and propranolol metabolism by cimetidine. | Q51655375 | ||
| Effect of omeprazole and cimetidine on plasma diazepam levels. | Q51742548 | ||
| Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. | Q51743867 | ||
| The interaction of omeprazole with rat liver cytochrome P450-mediated monooxygenase reactions in vitro and in vivo. | Q51773767 | ||
| Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. | Q51818926 | ||
| Cimetidine, antacids, and pulmonary aspiration. | Q51852294 | ||
| Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. | Q51873196 | ||
| Low clearance of cimetidine across the human placenta. | Q52595280 | ||
| Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin | Q53025508 | ||
| Cimetidine-induced liver injury. Report of three cases. | Q54266034 | ||
| Haemodynamic effects of the i.v. administration of cimetidine or ranitidine in the critically ill patient. A double-blind prospective study. | Q54397288 | ||
| Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. | Q54402781 | ||
| Cimetidine blocks testosterone synthesis. | Q54647642 | ||
| Cimetidine and serum prolactin. | Q55691235 | ||
| Propranolol steady-state pharmacokinetics are unaltered by omeprazole | Q57386578 | ||
| Histamine and noradrenaline decrease calcium-activated potassium conductance in hippocampal pyramidal cells | Q59066396 | ||
| Urticaria from ranitidine | Q62660090 | ||
| Hyperosmolar non-ketotic diabetes and cimetidine | Q66698957 | ||
| Cimetidine-associated thrombocytopenia | Q66703665 | ||
| Life-threatening arrhythmias and intravenous cimetidine | Q66979372 | ||
| Modulation of suppressor-cell activity by cimetidine in patients with common variable hypogammaglobulinemia | Q67274440 | ||
| Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal | Q67525684 | ||
| Induction of cytochrome P450IA genes (CYP1A) by omeprazole in the human alimentary tract | Q67576505 | ||
| Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists | Q67716663 | ||
| Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole | Q67863426 | ||
| The effect of ranitidine, cimetidine or famotidine on low-dose post-prandial alcohol absorption | Q67968758 | ||
| Omeprazole treatment does not affect the metabolism of caffeine | Q67970019 | ||
| Theophylline pharmacokinetics: effect of continuous versus intermittent cimetidine i.v. infusion | Q67976839 | ||
| Effect of omeprazole on gastric first-pass metabolism of ethanol | Q68127011 | ||
| Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies | Q68142727 | ||
| Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus | Q68287732 | ||
| Effects of various concomitant medications on gastric alcohol dehydrogenase and the first-pass metabolism of ethanol | Q68326088 | ||
| Cimetidine-induced mania in depressed patients | Q39558874 | ||
| The use of ranitidine in bone marrow transplantation. A review of 223 cases | Q39653030 | ||
| Pharmacokinetic interactions of cimetidine 1987. | Q39662361 | ||
| Ranitidine drug interactions--a literature review | Q39671379 | ||
| The treatment of gastrointestinal disease in pregnancy. | Q39738810 | ||
| Histamine H2-antagonist drug interactions in perspective: mechanistic concepts and clinical implications | Q40095987 | ||
| Inhibitors of Cytochrome P-450s and their mechanism of action | Q40317968 | ||
| Cimetidine-induced acute interstitial nephritis | Q40340966 | ||
| Cimetidine-induced neutropenia: a possible dose-related phenomenon | Q40711103 | ||
| Immunomodulatory properties of cimetidine in ARC patients | Q40785381 | ||
| Hyperpyrexia associated with intravenous cimetidine therapy. Report of a case | Q40805306 | ||
| Fever after cimetidine and ranitidine | Q40807340 | ||
| Effects of cimetidine on prolactin, LH, and sex steroid secretion in male and female volunteers | Q40917796 | ||
| Cimetidine in the treatment of acute alcoholic pancreatitis. A randomized, double-blind study | Q41079458 | ||
| Gynaecomastia associated with cimetidine | Q41494862 | ||
| Hypothalamic-Pituitary-Gonadal Dysfunction in Men Using Cimetidine | Q41514497 | ||
| Prolactin responses to cimetidine | Q41815108 | ||
| Antisecretory drugs and gastric cancer | Q41820551 | ||
| Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse: a randomized double-blind study with weekly endoscopic assessment. | Q41923222 | ||
| Mechanism for histamine H2-receptor induced cell-cycle changes in the bone marrow stem cell | Q41930027 | ||
| The effect of ranitidine on the plasma clearance and hepatic extraction of indocyanine green in patients with chronic liver disease | Q41953904 | ||
| Oral phenytoin pharmacokinetics during omeprazole therapy | Q42014803 | ||
| Omeprazole: effects on oxidative drug metabolism | Q42106854 | ||
| Effects of H2-receptor antagonists on ethanol metabolism in Japanese volunteers | Q42122933 | ||
| Cimetidine and adverse reactions: a meta-analysis of randomized clinical trials of short-term therapy | Q42199048 | ||
| Inhibition by omeprazole of adrenocortical response to ACTH: clinical studies and experiments on bovine adrenal cortex in vitro | Q42205460 | ||
| Recurrent myalgias associated with cimetidine | Q42221454 | ||
| Cimetidine hepatitis | Q42223538 | ||
| Ranitidine-associated hallucinations | Q42229886 | ||
| Immunologic studies in cimetidine-induced nephropathy and polymyositis | Q42244051 | ||
| Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states | Q42259171 | ||
| Cimetidine-induced interstitial nephritis with response to prednisone therapy | Q42259223 | ||
| Dose and serum concentration relationships in cimetidine-associated mental confusion | Q42261654 | ||
| Hepatitis following cimetidine administration | Q42263817 | ||
| Cimetidine-induced hepatitis. Electron microscopic observations and clinical pattern of liver injury | Q42268344 | ||
| A case report of cimetidine-induce depressive syndrome | Q42273253 | ||
| Cimetidine-induced renal failure | Q42332658 | ||
| Use of ranitidine, without mental confusion, in patients with renal failure | Q42592454 | ||
| Neurosensory adverse effects after phenylbutazone and misoprostol combined treatment | Q42702376 | ||
| Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. | Q43411735 | ||
| A comparative study of the effects of ranitidine and cimetidine on carbohydrate tolerance, growth hormone secretion and the hypothalamic-pituitary-gonadal axis in man. | Q43547373 | ||
| H2-antagonists and hepatitis | Q43740408 | ||
| Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. | Q43863401 | ||
| Ranitidine as an inhibitor of liver regeneration | Q43981489 | ||
| Inhibition of testosterone biosynthesis in testicular microsomes by various imidazole drugs. Comparative study with ketoconazole | Q44142106 | ||
| Influence of gastric acidity on the bioavailability of digoxin | Q44299461 | ||
| H-K-ATPase immunoreactivity in cortical and outer medullary collecting duct | Q68491387 | ||
| Effect of histamine H2-receptor antagonist, ranitidine on renal brush border and basolateral membranes | Q68494590 | ||
| Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochromes P-450 | Q68551587 | ||
| [Acute pancreatitis induced by cimetidine] | Q68692237 | ||
| Safety aspects of omeprazole | Q68728980 | ||
| Associations between drugs administered during pregnancy and congenital abnormalities of the fetus | Q68751892 | ||
| The comparative efficacy of cimetidine and ranitidine in controlling gastric pH in critically ill patients | Q68882822 | ||
| A study of the interaction between omeprazole and phenytoin in epileptic patients | Q68910380 | ||
| [Disorders of atrioventricular conduction caused by intravenous ranitidine] | Q69011448 | ||
| Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man | Q69021385 | ||
| High magnitude hepatic cytochrome P-450 induction by an N-substituted imidazole antimycotic, clotrimazole | Q69267280 | ||
| Bone marrow hypoplasia during intensive care: bone marrow culture studies implicating ranitidine in the suppression of haemopoiesis | Q69470586 | ||
| Agranulocytosis and ranitidine | Q69505245 | ||
| The clinical safety of omeprazole | Q69561615 | ||
| Stereoselective interaction of omeprazole with warfarin in healthy men | Q69605483 | ||
| Cimetidine and alcohol absorption | Q69721477 | ||
| Influence of cimetidine and ranitidine on ethanol pharmacokinetics | Q69848120 | ||
| CSF concentrations of ranitidine | Q69856349 | ||
| Effects of H2-blocking agents on hepatocytes in vitro: correlation with potential for causing hepatic disease in patients | Q69885220 | ||
| Effects of H2-receptor antagonists on the rat liver after partial hepatectomy or carbon tetrachloride-induced hepatic injury | Q69889511 | ||
| Effect of famotidine on hepatic hemodynamics and peptic ulcer | Q69899164 | ||
| Negative inotropic effects of famotidine | Q69905313 | ||
| Safety of nizatidine in clinical trials conducted in the USA and Europe | Q69911424 | ||
| Effects of short- and long-term administrations of famotidine and ranitidine on some pituitary, sexual and thyroid hormones | Q69911905 | ||
| Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial | Q69927046 | ||
| Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A) | Q69930872 | ||
| Effects of cimetidine on gastric alcohol dehydrogenase activity and blood ethanol levels | Q69936476 | ||
| Long-term treatment with cimetidine does not essentially affect the hypothalamic-pituitary-gonadal axis in man | Q69950244 | ||
| Overview of clinical safety with misoprostol | Q69968599 | ||
| Characterization of K-ATPase activity in distal nephron: stimulation by potassium depletion | Q70037265 | ||
| The effect of ranitidine and cimetidine on single-dose diltiazem pharmacokinetics | Q70078049 | ||
| Effects of cimetidine and ranitidine on splanchnic hemodynamics in patients with chronic liver disease | Q70081944 | ||
| Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report | Q70096815 | ||
| Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects | Q70113905 | ||
| Endocrine effects of acute and chronic cimetidine administration | Q70159645 | ||
| Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine | Q70174837 | ||
| Prenatal and neonatal exposure of male rat pups to cimetidine but not ranitidine adversely affects subsequent adult sexual functioning | Q70191076 | ||
| Is ethanol metabolism affected by oral administration of cimetidine and ranitidine at therapeutic doses? | Q70191151 | ||
| Ranitidine and cimetidine in renal transplantation: a clinical trial | Q70197197 | ||
| Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol | Q70212923 | ||
| [Ranitidine and cimetidine in the prevention of stress: ulcer hemorrhage a prospective comparative multicenter study] | Q70219827 | ||
| Hepatitis Associated with Ranitidine | Q70221448 | ||
| P433 | issue | 2 Suppl | |
| P304 | page(s) | 63S-80S | |
| P577 | publication date | 1995-02-01 | |
| P1433 | published in | Digestive Diseases and Sciences | Q15716711 |
| P1476 | title | Safety of acid-suppressing drugs | |
| P478 | volume | 40 |
| Q33914348 | A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy |
| Q35084804 | Abdominal pain during pregnancy. |
| Q74452130 | Gastric and duodenal ulcers during pregnancy |
| Q35084823 | Gastric and duodenal ulcers during pregnancy. |
| Q46724143 | Influence of CYP2C19*18 and CYP2C19*19 alleles on omeprazole 5-hydroxylation: in vitro functional analysis of recombinant enzymes expressed in Saccharomyces cerevisiae |
| Q33904367 | The risk of acute pancreatitis associated with acid-suppressing drugs |
| Q40378564 | The safety of H(2)-blockers use during pregnancy |
| Q36851934 | Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions |
Search more.